dr. jacobs on the use of ibrutinib in high-risk patients with cll
Published 6 years ago • 485 plays • Length 1:41Download video MP4
Download video MP3
Similar videos
-
1:33
dr. jacobs on the efficacy of ibrutinib and acalabrutinib in patients with mcl
-
0:55
dr. pinilla-ibarz on ibrutinib's efficacy in treating high-risk patients with cll
-
7:13
using ibrutinib in chronic lymphocytic leukemia (cll)
-
7:17
the use of ibrutinib in cll
-
9:02
efficacy and future role of ibrutinib in cll and mcl
-
25:09
cll: long-term updates on ibrutinib and idelalisib
-
11:28
adverse events of ibrutinib in chronic lymphocytic leukemia
-
4:22
progression on frontline ibrutinib in cll
-
9:39
introduction: upfront treatment in patients with chronic lymphocytic leukemia (cll)
-
2:29
real-world comparison of ttnt with ibrutinib or acalabrutinib in cll
-
10:21
mechanisms of ibrutinib resistance in chronic lymphocytic leukemia
-
25:38
cll: chemotherapy and ibrutinib based regimens
-
1:16
dr. woyach on ibrutinib and peripheral lymphocytosis in patients with chronic lymphocytic leukemia
-
2:15
dr. kay discusses the role of ibrutinib in cll
-
5:51
understanding ultra high-risk cll and advances with ibrutinib
-
2:42
dr. rogers discusses early intervention with ibrutinib in cll
-
2:06
the role of ibrutinib in the frontline treatment of young patients with cll
-
7:01
novel frontline combinations with ibrutinib in cll
-
1:03
dr. woyach on the safety of acalabrutinib versus ibrutinib in cll